<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423202</url>
  </required_header>
  <id_info>
    <org_study_id>AMB-321</org_study_id>
    <secondary_id>ARIES-2</secondary_id>
    <nct_id>NCT00423202</nct_id>
  </id_info>
  <brief_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.</brief_title>
  <official_title>Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy
      of ambrisentan in subjects with pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date>October 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline measured after 12 weeks of treatment compared to placebo in the Borg Dyspnea Index immediately following exercise, WHO functional class and SF-36 Health Survey.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical worsening of PAH.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety and tolerability of the study drug.</measure>
  </secondary_outcome>
  <enrollment>186</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ambrisentan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Current diagnosis of either PPH or PAH secondary to the scleroderma spectrum of
             disease, systemic lupus erythematosus, anorexigen use, or HIV infection at the
             Screening Visit

          -  Right heart catheterization, completed prior to Screening Visit must meet
             pre-specified hemodynamic criteria

          -  Female subjects of childbearing potential must have a negative serum pregnancy test
             and must agree to use a reliable double barrier method of contraception until study
             completion and for at least four weeks following their final study visit

          -  Male subjects must be informed of the potential risks of testicular tubular atrophy
             and infertility associated with taking this study drug and queried regarding his
             understanding of the potential risks as described in the Informed Consent Form

        Exclusion Criteria:

          -  PAH due to or associated with congenital heart disease, coronary artery disease, left
             heart disease, interstitial lung disease, chronic obstructive pulmonary disease,
             veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea

          -  Portopulmonary hypertension

          -  Bosentan within four weeks prior to Screening

          -  Phosphodiesterase type V inhibitor or chronic prostanoid therapy within four weeks
             prior to Screening

          -  IV inotrope use within two weeks prior to Screening

          -  ALT or AST lab value that is greater than 1.5 times the upper limit of normal

          -  Pulmonary function tests not meeting pre-specified criteria

          -  Contraindication to treatment with an ERA

          -  History of malignancies other than basal cell carcinoma of the skin or in situ
             carcinoma of the cervix within the past five years

          -  Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>April 15, 2009</last_update_submitted>
  <last_update_submitted_qc>April 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

